Turning Point Brands Announces First Quarter 2020 Results

LOUISVILLE, Ky.--()--Turning Point Brands (“TPB”) (NYSE: TPB), a leading provider of Other Tobacco Products (“OTP”) and adult consumer alternatives, today announced financial results for the first quarter ended March 31, 2020.

Results at a Glance

First Quarter 2020

(Comparisons vs. same period year-ago)

  • Net sales decreased 1.0% to $90.7 million;
  • Gross profit increased 2.4% to $41.4 million;
  • Net income decreased $3.3 million to $3.3 million, reflecting the inclusion of expensing PMTA costs incurred during the quarter;
  • Adjusted EBITDA increased 10.6% to $17.8 million (see Schedule A for a reconciliation to net income);
  • Diluted EPS of $0.16 and Adjusted Diluted EPS of $0.51 as compared to $0.33 and $0.43 in the year-ago period, respectively (see Schedule C for a reconciliation to Diluted EPS);

“Our results this quarter reflect the robust demand for our products even during challenging times. Sales performance was driven by mid-teens growth in our core Smokeless and Smoking segments partially aided by trade load-in as a response to strong customer demand and the uncertain environment. We estimate trade load-in impacted sales in our core tobacco segments by $2 million. Our NewGen segment also delivered better than expected results after we reorganized the business last quarter,” said Larry Wexler, President and CEO. “During this challenging environment, we are especially proud of the job our employees are doing to ensure the health and safety of each other and our local communities while maintaining our commitment to meet our customers’ needs. The dedication of TPB’s workforce to serve those needs has been remarkable.”

COVID-19 Impact

“As a result of the extraordinary situation we are facing, our focus during the quarter was on the safety and well-being of our colleagues and the communities and customers we serve. This focus serves as the basis for decisions we make as a company and how we react going forward,” said Wexler.

TPB implemented several changes to enhance safety and mitigate health risk in its work environment. For warehouse and manufacturing operations, these include split shifts, temperature scans, additional contactless hand sanitizing stations, protective equipment, social distancing guidelines, and increased cleaning and sanitization.

Unnecessary travel was suspended, and telecommuting is being facilitated where possible. Like many organizations, the company has changed the way it communicates through increased use of videoconferencing and has implemented tele-selling initiatives through its sales force. Some of these changes are likely to remain in-place even after this crisis and will lead to on-going cost savings. Annual compensation increases for corporate employees have been deferred other than those contractually required. In addition, new spending commitments are on hold as management cautiously manages through this environment.

To meet increased demand, the company hired additional employees for its Louisville facility and implemented wage increases for hourly employees. Production capacity was utilized to manufacture hand sanitizers with bottles being donated to hospitals, nursing homes and first responders in our local communities.

The company expects COVID-19 to impact results in the second quarter. A third-party cigar wrap manufacturer in the Dominican Republic temporarily closed for three weeks and is slowly ramping back up. In-person selling has been dramatically dampened, which will slow new product launches. Select budgeted annual price increases will be delayed. These issues will be partially offset by TPB’s growing B2C platforms. Management will continue to monitor this challenging environment closely and will make necessary adjustments as needed to make sure TPB continues to serve its customers, while also protecting the safety of its employees and communities.

Recent Events

On April 8, 2020, TPB and Standard Diversified Inc. (“SDI”) (NYSE: SDI) announced a definitive agreement under which SDI will be merged into a wholly-owned subsidiary of TPB in a tax-free downstream merger, in a transaction first announced by the companies in November 2019. Under the terms of the agreement, the holders of SDI’s Class A Common Stock and SDI’s Class B Common Stock (collectively, the “SDI Common Stock”) will receive in the aggregate, in return for their SDI Common Stock, TPB Voting Common Stock (“TPB Common Stock”) at a ratio of 0.97 of a share of TPB Common Stock for each share of TPB Common Stock held by SDI at the time of the merger. SDI will divest its assets prior to close such that the net liabilities at closing will not exceed $25,000 and the only assets that it shall retain is the remaining TPB stock holdings.

As a result of impacts due to COVID-19, FDA requested and received a modification to the United States District Court for the District of Maryland remedy order, resulting in a 120-day extension of the premarket tobacco application deadline for many e-cigarettes, cigars and other tobacco products. The new deadline of September 9, 2020 will allow TPB to utilize this additional time to bolster its premarket filings. The company continues to expect to spend a total of $15 to $18 million (inclusive of $2.2 million spent in 2019 and $5.9 million in the first quarter of 2020) on the PMTA process.

The company continues to actively engage in potential acquisition discussions with multiple candidates, but with no firm commitments currently. While the coronavirus has likely delayed the timing of completing such transactions, we have seen an increased pipeline of attractive opportunities as capital has become scarce.

Smokeless Products Segment (29% of total net sales in the quarter)

For the first quarter, Smokeless products net sales increased 17.5% to $26.5 million on continued double-digit volume growth of Stoker’s MST. Sales in chewing tobacco were flat as compared to the year-ago quarter. MST represented 59% of Smokeless revenues in the quarter, up from 52% a year earlier. In the quarter, total Smokeless segment volume increased 16.7% and price/mix advanced 0.8%.

“Our Stoker’s MST tubs line saw elevated demand at the end of the quarter as consumer trade down trends accelerated with a shift to larger volume purchases during the pandemic. We estimate trade load-in likely impacted sales by approximately $0.9 million during the quarter,” said Graham Purdy, Chief Operating Officer. “Stoker’s MST market share gains are poised to continue through same store sales gains along with further distribution expansion.”

For the quarter, Smokeless segment gross profit increased 14.9% to $13.9 million. Segment gross margin contracted 120 basis points to 52.4% primarily as a result of mix.

Smoking Products Segment (32% of total net sales in the quarter)

For the first quarter, net sales of Smoking products increased 13.3% to $28.9 million. Growth was driven by double-digit advances in US rolling papers, partially offset by a $0.5 million decline in non-focus cigars and MYO/Pipe. In the quarter, total Smoking segment volume increased 10.9% while price/mix increased 2.4%.

Zig-Zag continues to leverage its iconic positioning in rolling papers to successfully extend into new product lines. The expansion of organic hemp, paper cones, and unbleached papers continued during the quarter. Zig-Zag organic hemp papers are now in approximately 39,000 retail outlets while paper cones and unbleached papers are now in approximately 31,000 and 21,000 retail outlets, respectively.

“Our recent Zig-Zag introductions continue to perform well. According to MSAi, Zig-Zag’s share of the paper cone category climbed from 5% to 27% over the last year to position Zig-Zag as the #2 brand while Zig-Zag hemp paper is the #1 hemp paper brand with 28% share. We have also launched new initiatives to enhance Zig-Zag’s presence in other channels such as e-commerce and dispensaries both in the U.S. and in Canada that can be meaningful drivers of growth. Trade load-in likely impacted sales by approximately $1.1 million during the quarter,” said Purdy.

For the quarter, Smoking products gross profit increased 19.6% to $16.1 million. Segment gross margin expanded 300 basis points to 55.8% as a result of increased US rolling paper sales and a continued decline in the low margin cigar business.

NewGen (New Generation) Products Segment (39% of total net sales in the quarter)

For the first quarter, NewGen segment net sales contracted 19.0% to $35.3 million as a result of the continued impact of the vapor market disruption and the discontinuance of the V2 business. This was partially offset by positive contributions from CBD, Solace and other Nu-X products.

“We are encouraged by the results from the recent consolidation and streamlining of our business, despite lingering headwinds related to disruption in the vapor market that began in third quarter 2019. The NewGen segment is again profitable. In our B2C business, we experienced a strong rebound at the end of the quarter that has continued as customers shift to buying online,” said Purdy. “We successfully navigated our vape business through the disruption in the market last year and believe the trough is now behind us. We are now looking forward to completing the PMTA process after which there is significant potential for our proprietary brands. Furthermore, we are excited about the new products we have in the pipeline for Nu-X and continue to believe the Nu-X platform will serve as a strong engine for future growth.”

For the quarter, NewGen gross profit decreased $3.5 million to $11.4 million primarily as a result of the decline in net sales. Segment gross margin declined 180 basis points to 32.4% primarily due to recent product introductions. First quarter 2020 included $2.8 million of tariff expense compared to $2.0 million a year-ago.

Other Events and Performance Measures in the Fourth Quarter

First quarter consolidated selling, general and administrative (“SG&A”) expenses were $32.4 million compared to $28.4 million in 2019.

The first quarter had notable non-recurring impacts:

  • $5.9 million of FDA related expenses as compared to $0.0 million a year-ago; and
  • $1.0 million of transaction expenses principally related to M&A activity, including the announced SDI transaction.

The effective tax rate for the quarter was 22%.

Total debt at March 31, 2020 was $280.0 million. Net debt at March 31, 2020 was $180.6 million. Net debt at March 31, 2020 to rolling twelve months Adjusted EBITDA was 2.6x (see Schedule B for a reconciliation).

2020 Outlook

We are pleased that our first quarter results were above our expectations. We are also encouraged by government measures to support consumers and the economy. In-light of the changing landscape, we feel it is prudent to maintain our full year net sales and Adjusted EBITDA guidance provided February 26, 2020 until there is some clarity on the duration and the impact of the government reaction to the pandemic.

Absent any acquisitions, the company projects 2020 net sales to be $338 to $353 million. We project 2020 Adjusted EBITDA of $69 to $75 million. Our projections assume no upside from the PMTA process in 2020.

Stock compensation and non-cash incentive expense in 2020 is now projected to be $2.8 million (down from previous guidance of $3.3 million).

The company continues to expect to spend a total of $15 to $18 million (inclusive of $2.2 million spent in 2019 and $5.9 million in the first quarter of 2020) on the PMTA process, with expenses heavily weighted towards the first half of 2020.

Cash interest expense is projected to be $11 to $12 million and GAAP interest expense includes $7 million of debt discount amortization equal to the fair value of the equity components over the expected life of the 2024 convertible notes.

The company now expects the 2020 effective income tax rate to be 22% to 24% (compared to previous guidance of 21 to 23%).

Capital expenditures for 2020 are anticipated to be approximately $4 to $6 million (up from $4 million previously) as we are currently evaluating accelerating certain capital expenditure projects due to temporary tax code incentives.

Net Sales for the second quarter 2020 are expected to be $81 to $87 million.

Earnings Conference Call

As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for 10 a.m. Tuesday, April 28, 2020. Investment community participants should dial in ten minutes ahead of time using the toll-free number 844-889-4324 (International participants should call 412-317-9262). A live listen-only webcast of the call is available from the Events and Presentations section of the investor relations portion of the company website (www.turningpointbrands.com). A replay of the webcast will be available on the site three hours following the call.

Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including Adjusted EBITDA, Adjusted diluted EPS, Net Debt and Adjusted Operating Income. A reconciliation of these non-GAAP financial measures accompanies this release.

About Turning Point Brands, Inc.

Louisville, Kentucky-based Turning Point Brands, Inc. (NYSE: TPB) is a leading U.S. provider of Other Tobacco Products and adult consumer alternatives. TPB, through its focus brands generates solid cash flow which it uses to finance acquisitions, increase brand support and strengthen its capital structure. TPB does not sell cigarettes. More information about the company is available at its corporate website, www.turningpointbrands.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release speaks only as of the date hereof. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict these events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to:

  • declining sales of tobacco products, and expected continuing decline of sales, in the tobacco industry overall;
  • our dependence on a small number of third-party suppliers and producers;
  • the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption;
  • our business may be damaged by events outside of our suppliers’ control, such as the impact of epidemics (e.g., coronavirus), pollical upheavals, or natural disasters;
  • the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted;
  • failure to maintain consumer brand recognition and loyalty of our customers;
  • substantial and increasing U.S. regulation;
  • regulation of our products by the FDA, which has broad regulatory powers;
  • our products are subject to developing and unpredictable regulation, for example, current court action moving forward certain substantial Pre Market Tobacco Application obligations;
  • some of our products contain nicotine which is considered to be a highly addictive substance;
  • uncertainty related to the regulation and taxation of our NewGen products;
  • possible significant increases in federal, state and local municipal tobacco- and vapor-related taxes;
  • possible increasing international control and regulation;
  • our reliance on relationships with several large retailers and national chains for distribution of our products;
  • our amount of indebtedness;
  • the terms of our credit facilities, which may restrict our current and future operations;
  • intense competition and our ability to compete effectively;
  • uncertainty and continued evolution of markets containing our NewGen products;
  • significant product liability litigation;
  • the scientific community’s lack of information regarding the long-term health effects of electronic cigarettes, vaporizer and e-liquid use;
  • requirement to maintain compliance with master settlement agreement escrow account;
  • competition from illicit sources;
  • our reliance on information technology;
  • security and privacy breaches;
  • contamination of our tobacco supply or products;
  • infringement on our intellectual property;
  • third-party claims that we infringe on their intellectual property;
  • failure to manage our growth;
  • failure to successfully integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions;
  • fluctuations in our results;
  • exchange rate fluctuations;
  • adverse U.S. and global economic conditions;
  • sensitivity of end-customers to increased sales taxes and economic conditions;
  • failure to comply with certain regulations;
  • departure of key management personnel or our inability to attract and retain talent;
  • imposition of significant tariffs on imports into the U.S.;
  • reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors, potentially decreasing our stock price;
  • failure to maintain our status as an emerging growth company before the five-year maximum time period a company may retain such status;
  • our principal stockholders will be able to exert significant influence over matters submitted to our stockholders and may take certain actions to prevent takeovers;
  • our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or merger proposals, which may adversely affect the market price of our common stock;
  • our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors. These restrictions may affect the liquidity of our common stock and may result in Restricted Investors being required to sell or redeem their shares at a loss or relinquish their voting, dividend and distribution rights;
  • future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of equity or convertible securities may dilute your ownership in us;
  • we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock; and
  • our status as a “controlled company” could make our common stock less attractive to some investors or otherwise harm our stock price.

Financial Statements Follow:

Turning Point Brands, Inc.
Consolidated Statement of Income
(dollars in thousands except share data)
 

Three Months Ended

 March 31, 

 

2020

 

 

2019

 

Net sales

 $

                    90,689

 

 $

                    91,628

 

Cost of sales

 

                       49,258

 

 

                       51,164

 

Gross profit

 

                       41,431

 

 

                       40,464

 

Selling, general, and administrative expenses

 

                       32,394

 

 

                       28,429

 

Operating income

 

                         9,037

 

 

                       12,035

 

Interest expense, net

 

                         4,994

 

 

                         3,856

 

Investment income

 

                             (91

)

 

                           (144

)

Net periodic income, excluding service cost

 

                             (87

)

 

                             (11

)

Income before income taxes

 

                         4,221

 

 

                         8,334

 

Income tax expense

 

                            946

 

 

                         1,774

 

Consolidated net income

 $

                      3,275

 

 $

                      6,560

 

 
Basic income per common share:
Consolidated net income

 $

                        0.17

 

 $

                        0.34

 

Diluted income per common share:
Consolidated net income

 $

                        0.16

 

 $

                        0.33

 

Weighted average common shares outstanding:
Basic

 

                19,689,446

 

 

                19,559,596

 

Diluted  

 

                20,106,800

 

 

                20,045,964

 

 
Supplemental disclosures of statement of income information:
Excise tax expense

 $

                      5,041

 

 $

                      4,976

 

FDA fees

 $

                         129

 

 $

                         134

 

 

Turning Point Brands, Inc.
Consolidated Balance Sheet
(dollars in thousands except share data)
(unaudited)
March 31, December 31,
ASSETS

 

2020

 

 

2019

 

Current assets:
Cash

 $

                        99,406

 

 $

                        95,250

 

Accounts receivable, net of allowances of $256 in 2020 and $280 in 2019

 

                             4,310

 

 

                             6,906

 

Inventories

 

                           69,195

 

 

                           70,979

 

Other current assets

 

                           18,868

 

 

                           16,115

 

Total current assets

 

                         191,779

 

 

                         189,250

 

Property, plant, and equipment, net

 

                           13,404

 

 

                           13,816

 

Right of use assets

 

                           13,036

 

 

                           12,130

 

Deferred financing costs, net

 

                                860

 

 

                                890

 

Goodwill

 

                         154,282

 

 

                         154,282

 

Other intangible assets, net

 

                           33,044

 

 

                           33,469

 

Master Settlement Agreement (MSA) escrow deposits

 

                           32,074

 

 

                           32,074

 

Other assets

 

                           10,841

 

 

                           10,673

 

Total assets

 $

                      449,320

 

 $

                      446,584

 

 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

 $

                        17,348

 

 $

                        14,126

 

Accrued liabilities

 

                           28,754

 

 

                           26,520

 

Current portion of long-term debt

 

                           12,000

 

 

                           15,240

 

Revolving credit facility

 

                                   -  

 

 

                                   -  

 

Total current liabilities

 

                           58,102

 

 

                           55,886

 

Notes payable and long-term debt

 

                         267,977

 

 

                         268,951

 

Deferred income taxes

 

                             1,495

 

 

                             1,572

 

Lease liabilities

 

                           11,673

 

 

                           11,067

 

Other long-term liabilities

 

                             4,762

 

 

                             2,523

 

Total liabilities

 

                         344,009

 

 

                         339,999

 

 
Commitments and contingencies
 
Stockholders' equity:
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-

 

                                   -  

 

 

                                   -  

 

Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,723,080 issued shares,  
19,588,950 outstanding shares at March 31, 2020, and 19,680,673 issued and outstanding shares
at December 31, 2019

 

                                197

 

 

                                197

 

Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000;
issued and outstanding shares -0-

 

                                   -  

 

 

                                   -  

 

Additional paid-in capital

 

                         126,151

 

 

                         125,469

 

Cost of repurchased common stock
(134,130 shares at March 31, 2020 and 0 shares at December 31, 2019)

 

                            (2,627

)

 

                                   -  

 

Accumulated other comprehensive loss

 

                            (5,379

)

 

                           (3,773

)

Accumulated deficit

 

                          (13,031

)

 

                         (15,308

)

Total stockholders' equity

 

                         105,311

 

 

                         106,585

 

Total liabilities and stockholders' equity

 $

                      449,320

 

 $

                      446,584

 

 

Turning Point Brands, Inc.
Consolidated Statement of Cash Flows
(dollars in thousands)
 

 For the three months ended March 31,

 

2020

 

 

2019

 

Cash flows from operating activities:
Consolidated net income

 $

 

                                  3,275

 

 $

 

                                 6,560

 

Adjustments to reconcile net income to net cash provided by operating activities:
Loss on disposal of property, plant, and equipment

 

                                           -  

 

 

                                         23

 

Depreciation expense

 

                                        851

 

 

                                       531

 

Amortization of other intangible assets

 

                                        425

 

 

                                       359

 

Amortization of debt discount and deferred financing costs

 

                                     2,237

 

 

                                       237

 

Deferred income taxes

 

                                        545

 

 

                                        (29

)

Stock compensation expense

 

                                        455

 

 

                                       466

 

Noncash lease expense

 

                                          13

 

 

                                          -  

 

Changes in operating assets and liabilities:
Accounts receivable

 

                                     2,596

 

 

                                   (1,726

)

Inventories

 

                                     1,784

 

 

                                       366

 

Other current assets

 

                                    (2,420

)

 

                                    2,984

 

Other assets

 

                                       (130

)

 

                                      (427

)

Accounts payable

 

                                     3,210

 

 

                                    8,229

 

Accrued postretirement liabilities

 

                                         (27

)

 

                                          (9

)

Accrued liabilities and other

 

                                     1,913

 

 

                                   (3,539

)

Net cash provided by operating activities

 

                                   14,727

 

 

                                  14,025

 

 
Cash flows from investing activities:
Capital expenditures

 $

 

                                    (877

)

 $

 

                                   (886

)

Restricted cash, MSA escrow deposits

 

                                           -  

 

 

                                    1,702

 

Net cash (used in) provided for by investing activities

 

                                       (877

)

 

                                       816

 

 
Cash flows from financing activities:  
Payments of 2018 first lien term loan

 

                                    (2,000

)

 

                                   (2,000

)

Payments of 2018 revolving credit facility

 

                                           -  

 

 

                                 (12,000

)

Payment of dividends

 

                                       (886

)

 

                                      (880

)

Payment of IVG note

 

                                    (4,240

)

 

                                          -  

 

Payments of financing costs

 

                                       (168

)

 

                                          -  

 

Common stock repurchased

 

                                    (2,627

)

 

                                          -  

 

Exercise of options

 

                                        227

 

 

                                       187

 

Redemption of options

 

                                           -  

 

 

                                        (12

)

Net cash used in financing activities

 $

 

                                 (9,694

)

 $

 

                              (14,705

)

 
Net increase in cash

 $

 

                                  4,156

 

 $

 

                                    136

 

 
Cash, beginning of period:
Unrestricted

 $

 

                                95,250

 

 $

 

                                 3,306

 

Restricted

 

                                   32,074

 

 

                                    2,361

 

           Total cash at beginning of period

 $

 

                              127,324

 

 $

 

                                 5,667

 

 
 
Unrestricted

 $

 

                                99,406

 

 $

 

                                 1,741

 

Restricted

 

                                   32,074

 

 

                                    4,062

 

           Total cash at end of period

 $

 

                              131,480

 

 $

 

                                 5,803

 

 Non-GAAP Financial Measures

 

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted diluted EPS, Net Debt and Adjusted Operating Income.  We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations.  Adjusted EBITDA, Adjusted diluted EPS, Net Debt and Adjusted Operating Income are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors.  We believe that EBITDA, Adjusted EBITDA, Adjusted diluted EPS and Adjusted Operating Income are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.

 

We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation and amortization.  We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.  We define “Adjusted diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance.  We define “Net Debt” as total debt less cash.  We define “Adjusted Operating Income” as operating income excluding depreciation, amortization, LIFO, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.

 

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP.  EBITDA, Adjusted EBITDA Adjusted diluted EPS and Adjusted Operating Income exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and is subject to inherent limitations.  In addition, other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure. 

 

In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.

Schedule A
 
 
 
Turning Point Brands, Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(dollars in thousands)

Three Months Ended

 March 31, 

 

2020

 

 

2019

 

Consolidated net income

 $

 

 

 

 

               3,275

 

 $

 

 

 

 

              6,560

 

Add:
Interest expense, net

 

                  4,994

 

 

                 3,856

 

Income tax expense

 

                     946

 

 

                 1,774

 

Depreciation expense

 

                     851

 

 

                    531

 

Amortization expense

 

                     425

 

 

                    359

 

EBITDA

 $

 

 

 

 

             10,491

 

 $

 

 

 

 

            13,080

 

  Components of Adjusted EBITDA
Other (a)

 

                      (87

)

 

                    (79

)

Stock options, restricted stock, and incentives expense (b)

 

                     455

 

 

                    715

 

Transactional expenses and strategic initiatives (c)

 

                  1,049

 

 

                    910

 

New product launch costs (d)

 

                        -  

 

 

                    442

 

Corporate and vapor restructuring (e) 

 

                        -  

 

 

                 1,004

 

FDA PMTA (f)

 

                  5,874

 

 

                      -  

 

Adjusted EBITDA

 $

 

 

 

 

             17,782

 

 $

 

 

 

 

            16,072

 

 
       
(a)  Represents LIFO adjustment, non-cash pension/postretirement expense (income) and foreign exchange hedging.
(b)  Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs.
(c)  Represents the fees incurred for transaction expenses and strategic initiatives.
(d)  Represents product launch costs of our new product lines.
(e)  Represents costs associated with corporate and vapor restructuring including severance and inventory reserves.
(f)  Represents costs associated with applications related to FDA PMTA.
Schedule B
 
Turning Point Brands, Inc.
Reconciliation of GAAP Total Debt to Net Debt
(dollars in thousands)
 
March 31, December 31,

 

 

 

2020

 

 

2019

 
Cash

 $

                          99,406

 $

                        95,250

 
Total Debt

 $

                        279,977

 $

                      284,191

 
Net Debt

 $

                        180,571

 $

                      188,941

 
Leverage Ratio (a) 2.6x 3.1x
(a) Leverage ratio is calculated by net debt / adjusted EBITDA.
Turning Point Brands, Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA

April 1, 2019, to March 31, 2020

(dollars in thousands)
 
Rolling 1st Quarter 4th Quarter 3rd Quarter 2nd Quarter

12 Months

 

2020

 

 

2019

 

 

2019

 

2019

 

 
Consolidated net income (loss)

 $

                          10,489

 

 $

                          3,275

 

 $

               (12,265

)

 $

                  6,274

 $

                     13,205

 

Add:
Interest expense, net

 

                             18,480

 

 

                             4,994

 

 

                      6,109

 

 

                     3,641

 

                          3,736

 

Loss on extinguishment of debt

 

                               1,308

 

 

                                   -  

 

 

                            -  

 

 

                     1,158

 

                             150

 

Income tax expense (benefit)

 

                               1,216

 

 

                                946

 

 

                    (4,945

)

 

                     2,236

 

                          2,979

 

Depreciation expense

 

                               2,958

 

 

                                851

 

 

                         783

 

 

                        692

 

                             632

 

Amortization expense

 

                               1,517

 

 

                                425

 

 

                         372

 

 

                        356

 

                             364

 

 
EBITDA

 $

                          35,968

 

 $

                        10,491

 

 $

                 (9,946

)

 $

                14,357

 $

                     21,066

 

Components of Adjusted EBITDA

Other

 

                                  352

 

 

                                (87

)

 

                         385

 

 

                        151

 

                              (97

)

Stock options, restricted stock, and incentives expense

 

                               4,366

 

 

                                455

 

 

                      1,399

 

 

                     1,314

 

                          1,198

 

Transactional expenses and strategic initiatives

 

                               1,903

 

 

                             1,049

 

 

                         197

 

 

                        470

 

                             187

 

New product launch costs

 

                               5,743

 

 

                                   -  

 

 

                      2,494

 

 

                     1,979

 

                          1,270

 

Corporate and vapor restructuring

 

                             18,210

 

 

                                   -  

 

 

                    17,795

 

 

                        265

 

                             150

 

FDA PMTA

 

                               8,027

 

 

                             5,874

 

 

                      1,912

 

 

                        241

 

                                -  

 

Vendor settlement

 

                             (5,522

)

 

                                   -  

 

 

                            -  

 

 

                           -  

 

                         (5,522

)

Adjusted EBITDA

 $

                          69,047

 

 $

                        17,782

 

 $

                 14,236

 

 $

                18,777

 $

                     18,252

 

 
 
Net Debt / 12 months ended March 31, 2020, rolling Adjusted EBITDA 2.6x
 
Schedule C      
       
Turning Point Brands      
Reconciliation of GAAP diluted EPS to Adjusted diluted EPS      
(dollars in thousands except share data) Three Months Ended
  March 31, 
 

 

2020

 

 

 

2019

 

GAAP EPS

 $

                        0.16

 

 

 $

                       0.33

 

Other (a)

 $

                       (0.00

)

 

 

                        (0.00

)

Stock options, restricted stock, and incentives expense (b)

 $

                        0.02

 

 

                          0.03

 

Transactional expenses and strategic initiatives (c)

 $

                        0.04

 

 

 

                          0.03

 

New product launch costs (d)

 $

                            -  

 

 

 

                          0.02

 

Corporate and vapor restructuring (e)

 $

                            -  

 

 

                          0.04

 

FDA PMTA (f)

 $

                        0.22

 

 

 

                             -  

 

Amortization of debt discount (g)

 $

                        0.07

 

 

                             -  

 

Tax benefit (h)

 $

                       (0.00

)

 

                        (0.02

)

Adjusted diluted EPS

 $

                        0.51

 

 

 $

                       0.43

 

       
(a) Represents LIFO adjustment, non-cash pension/ postretirement expense (income) and foreign exchange hedging reporting tax effected at the quarterly effective tax rate.
(b)  Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly effective tax rate.
(c)  Represents the fees incurred for transaction expenses and strategic initiatives tax effected at the quarterly effective tax rate.
(d)  Represents product launch costs of our new product lines tax effected at the quarterly effective tax rate.
(e) Represents costs associated with corporate and vapor restructuring including severance and inventory reserves tax effected at the quarterly effective tax rate .
(f) Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly effective tax rate.
(g) Represents non-cash amortization of debt discount tax effected at the quarterly effective tax rate.

(h) Represents adjustment from quarterly effective tax rate to annual projected effective tax rate of 23%.

 

Schedule D
                               
Turning Point Brands, Inc.
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and GAAP Operating Income to Adjusted Operating Income

(dollars in thousands)

  Consolidated   Smokeless   Smoking   NewGen
  1st Quarter   1st Quarter   1st Quarter   1st Quarter   1st Quarter   1st Quarter   1st Quarter   1st Quarter
 

 

2020

 

 

2019

 

 

 

2020

 

 

2019

 

 

 

2020

 

 

2019

 

 

 

2020

 

 

2019

                               
Net sales

 $

                                90,689

 

 $

                            91,628

 

 

 $

                         26,495

 

 $

               22,544

 

 

 $

               28,914

 

 $

               25,519

 

 

 $

               35,280

 

 $

               43,565

                               
Gross profit

 $

                                41,431

 

 $

                            40,464

 

 

 $

                         13,874

 

 $

               12,073

 

 

 $

               16,132

 

 $

               13,484

 

 

 $

               11,425

 

 $

               14,907

Adjustments:                              
  LIFO adjustment

 

                                           -  

 

 

                                    (24

)

 

 

                                    -  

 

 

                       (24

)

 

 

                          -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

                               
Adjusted gross profit

 $

                                41,431

 

 $

                            40,440

 

 

 $

                         13,874

 

 $

               12,049

 

 

 $

               16,132

 

 $

               13,484

 

 

 $

               11,425

 

 $

               14,907

                               
Operating income

 $

                                  9,037

 

 $

                            12,035

 

 

 $

                           9,746

 

 $

                 7,487

 

 

 $

               12,417

 

 $

                 9,946

 

 

 $

                    477

 

 $

                 2,838

Adjustments:                              
  LIFO adjustment

 

                                           -  

 

 

                                    (24

)

 

 

                                    -  

 

 

                       (24

)

 

 

                          -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

  Foreign exchange hedging

 

                                           -  

 

 

                                    (71

)

 

 

                                    -  

 

 

                          -  

 

 

 

                          -  

 

 

                       (71

)

 

 

                          -  

 

 

                          -  

  Transactional expenses and strategic initiatives

 

                                     1,049

 

 

                                    910

 

 

 

                                    -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

  New product launch costs

 

                                           -  

 

 

                                    442

 

 

 

                                    -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

 

 

 

                          -  

 

 

                       442

  Corporate and vapor restructuring

 

                                           -  

 

 

                                 1,004

 

 

 

                                    -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

 

 

 

                          -  

 

 

                       508

  FDA PMTA

 

                                     5,874

 

 

                                       -  

 

 

 

                                    -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

 

 

 

                          -  

 

 

                          -  

Adjusted operating income

 $

                                15,960

 

 $

                            14,296

 

 

 $

                           9,746

 

 $

                 7,463

 

 

 $

               12,417

 

 $

                 9,875

 

 

 $

                    477

 

 $

                 3,788

                               

 

 

Contacts

Robert Lavan, Senior Vice President, CFO
ir@tpbi.com (502) 774-9238

Contacts

Robert Lavan, Senior Vice President, CFO
ir@tpbi.com (502) 774-9238